Exploring How Advanced Human-Derived Pre-Clinical Systems Can Be Optimized for ADCs to Predict & Mitigate Toxicities
Time: 9:30 am
day: Scientific Program Day Two
Details:
- Examining the benefits of patient-derived xenograft (PDX) models in replicating tumor microenvironment-driven toxicity, specifically when developing neuronal cultures in vitro to evaluate the cytotoxicity index with the efficacy and on neurons
- Discussing the neuronal toxicities mediated by the bystander capable payload to manage the heterogeneity of Glioblastoma
- Evaluating the limitations of scalability, reproducibility, and long-term viability of patientderived cell cultures for ADC toxicity testing
